- Posted By: TreehillPartners
- In: Drug Development
- Posted By: TreehillPartners
- In: Drug Development
- Posted By: TreehillPartners
- In: Drug Development
The pharmaceutical industry is at the commercial interface between innovation, patients, caregivers and payers. With U.S. elections now behind, the question is out about how
Read the full interview of Ali Pashazadeh, Treehill Partners CEO at Genetic Engineering & Biotechnology News (GEN) – a renown publication where GEN’s unique news
Read Ali Pashazadeh’s viewpoints on pricing uncertainty, dealmaking, and industry checks and balances along the thoughts of other industry KOLs in this recent Firstword Pharma
Ali Pashazadeh, Treehill Partners CEO was part of a series of interviewees for Mari Serebrov’s viewpoints poll right after the U.S. elections 2024. Read on
Clinical Trials Arena, a leading flagship GlobalData publication has a headline article today about the BioSecure Act and its potential effects on the drug development
Introducing a mechanism for patenting a new potential use for a drug technology for a period of time after publishing clinical trial data, could be
Ali Pashazadeh, Treehill’s CEO, contributes to an article in Mergermarket summarising current trends in the European immunology, inflammatory and autoimmune marketplaces, including the current trends in M&A.
It wouldn’t be accurate to say that surgeon-turned-healthcare investment banker and consultant Dr. Ali Pashazadeh traded his scalpels for spreadsheets. In fact, he still wields
Using a mechanistic pathway or agent to achieve something else than it was designed to do, leaves questions unanswered that will become clear only over
Ali Pashazadeh, Treehill Partners CEO, adds to a discussion on Clinical Trials Arena about how the correct interpretation and use of data is key to
